Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03703492 · ClinicalTrials.gov registry record · Phase 2

Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS

A Phase 2 study, sponsored by University of Wisconsin, Madison.

Completed
Registry status
Phase 2
Development phase
12
Enrollment target

NCT03703492 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03703492, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
Phase 2
Development phase
12 participants
Enrollment target

Study Summary

This prospective, one-arm study which will enroll participants with biopsy-proven DCIS scheduled for diagnostic breast MRI for preoperative staging/extent of disease evaluation as part of standard of care. Eligible participants will be consented for participation in the research study which includes a directed breast PET/MRI with 18F-FES. 18F-FES uptake of the known malignancy will be measured on the PET/MRI examination using standardized uptake values (SUV) and tumor-to-normal tissue ratios.

Interventions

  • DRUG (18F)FES
  • DRUG Gadobenate dimeglumine

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2019-01-03
Est. Completion 2024-01-02
Phase Phase 2

Sponsor

University of Wisconsin, Madison

1,039 total trials

What the Registry Record Tells You About NCT03703492

The ClinicalTrials.gov registry entry for NCT03703492 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which (18F)FES is the first listed.

NCT03703492 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03703492 about?

NCT03703492 is a clinical study titled "Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS". This prospective, one-arm study which will enroll participants with biopsy-proven DCIS scheduled for diagnostic breast MRI for preoperative staging/extent of disease evaluation as part of standard of care. Eligible participants will be consented for participation in the research study which includes...

What is the current status of trial NCT03703492?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2019-01-03. Estimated completion is 2024-01-02.

What interventions are being tested in trial NCT03703492?

The interventions under investigation include: (18F)FES (DRUG), Gadobenate dimeglumine (DRUG).

Who is sponsoring clinical trial NCT03703492?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.